Scilex Pharmaceuticals is developing Ztildo, a lidocaine patch targeted at post‑herpetic neuralgia. Ztildo uses licensed drug‑delivery technology from an unnamed Japanese company and is formulated with a fraction of the lidocaine dose found in Lidoderm. The company plans to complete clinical testing later this year and file a new drug application with the FDA at the start of next year. If approved, Scilex expects to launch as soon as late 2015 and position Ztildo to compete when Lidoderm's patent expires. Scilex raised $5 million from private investors, according to regulatory filings, to support completion of the trials. Founded in 2012 and based in the greater Philadelphia area, the company estimates the Lidoderm brand created a market opportunity in excess of $1 billion.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2014